Indoco Remedies Ltd - Stock Valuation and Financial Performance

BSE: 532612 | NSE: INDOCO | Pharmaceuticals & Drugs | Small Cap

Indoco Remedies Share Price

346.10 -5.90 -1.68%
as on 12-Apr'24 16:59

DeciZen - make an informed investing decision on Indoco Remedies

Overall Rating
Bole Toh

1. Quality

2. Valuation

Somewhat Undervalued

3. Price Trend

Semi Strong

Indoco Remedies stock performance -

mw4me loader
P/E Ratio (SA):
30.54
Market Cap:
3,190.4 Cr.
52-wk low:
307
52-wk high:
417

Is Indoco Remedies Ltd an attractive stock to invest in?

1. Is Indoco Remedies Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Indoco Remedies Ltd is a average quality company.

2. Is Indoco Remedies Ltd undervalued or overvalued?

The key valuation ratios of Indoco Remedies Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.

3. Is Indoco Remedies Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Indoco Remedies Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Indoco Remedies:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Indoco Remedies Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 13.2%15.5%14.2%9.9%6%1.2%4.5%11%15.1%12.8%-
Value Creation
Index
-0.10.10.0-0.3-0.6-0.9-0.7-0.20.1-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 7288541,0051,0721,0389681,1061,2401,5401,6671,755
Sales YoY Gr.-17.3%17.7%6.7%-3.2%-6.8%14.3%12.1%24.1%8.3%-
Adj EPS 6.399.38.44.4-0.32.71016.615.411.3
YoY Gr.-43.2%3.6%-10.2%-47.9%-107.1%NA278.9%64.9%-6.9%-
BVPS (₹) 49.656.362.670.773.371.773.883.498.1111.4117.9
Adj Net
Profit
57.982.885.87740.2-2.924.492.6153142104
Cash Flow from Ops. 99.911011287.812313212382.2174176-
Debt/CF from Ops. 0.90.91.23.22.32.22.13.21.41.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 9.6%9.9%14.7%8.3%
Adj EPS 10.5%28.7%79.9%-6.9%
BVPS9.4%8.7%14.7%13.5%
Share Price 9.5% 11.9% 4% 5%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
13.31715.712.56.1-0.43.612.818.214.79.9
Op. Profit
Mgn %
16.219.417.214.512.781117.621.217.215.1
Net Profit
Mgn %
89.78.57.23.9-0.32.27.59.98.56
Debt to
Equity
0.20.20.20.40.40.50.40.30.30.3-
Working Cap
Days
16316216518020520918018318519687
Cash Conv.
Cycle
71646264747563768910338

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 14.65%

Net Profit is growing at healthy rate in last 3 years 79.86%

Return on Equity has declined versus last 3 years average to 9.90%

Sales growth is not so good in last 4 quarters at 8.94%

Latest Financials - Indoco Remedies Ltd.

Standalone Consolidated
TTM EPS (₹) 11.3 11
TTM Sales (₹ Cr.) 1,755 1,778
BVPS (₹.) 117.9 117.6
Reserves (₹ Cr.) 1,068 1,065
P/BV 2.94 2.94
PE 30.54 31.41
From the Market
52 Week Low / High (₹) 307.00 / 416.95
All Time Low / High (₹) 13.87 / 529.70
Market Cap (₹ Cr.) 3,190
Equity (₹ Cr.) 18.4
Face Value (₹) 2
Industry PE 48

Management X-Ray of Indoco Remedies:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Indoco Remedies

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales7288541,0051,0721,0389681,1061,2401,5401,667
Operating Expenses 6106888379179078919851,0231,2141,382
Manufacturing Costs5873107119128135149167227247
Material Costs269298348360346320330354457521
Employee Cost 129140181216220231255273295321
Other Costs 154177201223212204250229235293
Operating Profit 11816516815513177121218326285
Operating Profit Margin (%) 16.2%19.4%16.7%14.4%12.7%7.9%10.9%17.5%21.2%17.1%
Other Income 4246875973
Interest 1910126242126221725
Depreciation 31476163687271737971
Exceptional Items 0000000000
Profit Before Tax 72109999148-929131236192
Tax 142717147-64398250
Profit After Tax 5883827741-32492155141
PAT Margin (%) 8.0%9.7%8.2%7.2%4.0%-0.3%2.2%7.4%10.0%8.5%
Adjusted EPS (₹)6.39.08.98.44.5-0.32.610.016.815.3
Dividend Payout Ratio (%)22%18%18%19%22%-97%11%15%13%15%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 4575185766526766616807699041,026
Share Capital 18181818181818181818
Reserves 4395005586336576436627508861,008
Minority Interest0000000000
Debt7086124251233242203214200263
Long Term Debt141338132123129979796144
Short Term Debt577386118110113106117104119
Trade Payables69119131164149171166115135126
Others Liabilities 130119113123160149191238342299
Total Liabilities 7268429451,1891,2181,2231,2401,3361,5811,715

Fixed Assets

Gross Block4815476427698859341,1271,1781,2361,406
Accumulated Depreciation156208268330396467537608681745
Net Fixed Assets325339373440489468590570555661
CWIP 446355911361855168122113
Investments 011833222220
Inventories108146164185193183208238311326
Trade Receivables137154188216208194209234297351
Cash Equivalents 13151262123638141912
Others Assets98124134193178153142210275232
Total Assets 7268429451,1891,2181,2231,2401,3361,5811,715

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 1001101128812313212382174176
PBT 72109999148-929131236192
Adjustment 50657964988910011087121
Changes in Working Capital -8-40-38-44-1456-2-139-109-75
Tax Paid -15-25-27-24-10-4-4-20-41-61
Cash Flow From Investing Activity -41-88-113-171-135-104-56-67-121-205
Capex -41-89-97-189-137-93-58-77-124-188
Net Investments 00-171600000-2
Others 10222-112103-15
Cash Flow From Financing Activity -58-210132-39-16-64-30-4423
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -20-932115713-31-14054
Interest Paid -20-14-13-13-19-21-22-23-15-27
Dividend Paid -12-15-33-2-18-11-3-3-14-21
Others -7171433-93-710-1516
Net Cash Flow 11050-51123-148-7
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)13.2916.9815.0312.616.21-0.433.6212.7518.4714.64
ROCE (%)16.8320.6616.7811.847.621.245.7915.5923.3117.42
Asset Turnover Ratio1.051.11.131.030.870.790.90.961.061.01
PAT to CFO Conversion(x)1.721.331.371.143N/A5.130.891.121.25
Working Capital Days
Receivable Days65616267747667656371
Inventory Days50545658667165666570
Payable Days8610812414216218218614510092

Indoco Remedies Ltd Stock News

Indoco Remedies Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Indoco Remedies on 12-Apr-2024 16:59 is ₹346.1.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 12-Apr-2024 16:59 the market cap of Indoco Remedies stood at ₹3,190.4.
The latest P/E ratio of Indoco Remedies as of 12-Apr-2024 16:59 is 30.54.
The latest P/B ratio of Indoco Remedies as of 12-Apr-2024 16:59 is 2.94.
The 52-week high of Indoco Remedies is ₹416.9 and the 52-week low is ₹307.0.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Indoco Remedies is ₹1,755 ( Cr.) .

About Indoco Remedies Ltd

Indoco Remedies Limited is a Public Limited Company domiciled in India and incorporated under the provision of the Companies Act, VII of 1913. Its Shares are listed on two stock exchanges in India i.e Bombay Stock Exchange and National Stock Exchange. The company has decades of presence in the Indian Pharma market and a strong foothold in the international market.

Indoco has strengthened its wings in the international markets and offers complete solutions, including product development, manufacture and supply of Finished Dosages, APIs and Intermediates to generic companies worldwide. The company has a large basket of products backed by ANDAs / eCTD Dossiers and Drug Master Files (DMFs).

Expertise in Research & Development, backward integration in API in select products, own CRO set-up, excellence in Finished Dosages manufacturing and a strong customer base will ensure consistent growth in the Company’s Domestic, as well as International business.

Business area of the company

Indoco Remedies is engaged in the manufacturing and marketing of Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs). The Company caters to both domestic and International markets.

Awards and Accolades

Patent Award

  • Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
  • Indoco wins the IDMA Formulations Patent Award 2017-18 for 1 International and 2 Indian patents -Olopatadine, Gliclazide & Brinzolamide Ophthalmic Solution
  • Indoco receives the 'IDMA Best Patent Award' for four API Process Patents in 2017
  • Indoco Honoured with the 'IDMA Best Patent Award' for Three International Patents in 2016
  • Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category in 2016
  • Indoco receives European Patent approval for Lacosamide
  • Indoco honoured with 'Certificate of Appreciation' (Bulk Drugs) in 2015
  • Indoco wins 'Patent Appreciation Award' at 52nd IDMA Award Function in 2014

Awards

  • Rajhans Pratisthan Award 2017 for Mr. Suresh G. Kare and Indoco for commendable CSR initiatives carried out under the banner 'SUMATI SANGOPAN'
  • Mr. Suresh G. Kare receives 'The Pride of Goa' Award 2016 by the Goa Chamber of Commerce & Industry
  • Mr. Suresh G. Kare honoured with 'Lifetime Achievement Award' at the hands of The Chief Minister of Goa in 2016
  • Mr. Suresh G. Kare honoured with Udyogshree Life Time Achievement Award by Hon'ble Defence Minister, Mr. Manohar Parrikar in 2013
  • Mr. Suresh G. Kare received the prestigious Excellence Award-2004 from Pharma Business And Technology.
  • Ms. Aditi Kare Panandikar receives the 'Leader of the Year' Award at the UBM India Pharma Awards in 2016
  • Ms. Aditi Kare Panandikar receives the 'Businesswoman of the Year' award at the Business Goa Awards for Corporate Excellence in 2016
  • Ms. Aditi Kare Panandikar received the 2015 Jack L. Beal Post-baccalaureate Alumni Award from 'The Ohio State University College of Pharmacy' in USA

Goa Plant I Award

  • The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2008 - Silver Award, for the third time.
  • The Solid Dosage Forms and Externals Facility received the IDMA Quality Excellence Awards 2003 - Formulations - Gold Award, second time since commissioned in 1997.

Goa Plant II Award

  • The Sterile Facility received the IDMA Quality Excellence Awards 2008 - Gold Award, for the third time.
  • The Sterile Facility for Injectibles and Ophthalmics received the IDMA Quality Excellence Awards 2003 - Formulations - Silver Award.

Milestone

1993

  • R&D recognized by DSIR

1997

  • Commencement of production in Goa Plant I

1999

  • New Corporate Office at Indoco House
  • Acquisition of Warren. Indoco makes presence in Ophthalmic & Dental Segments
  • Turnover crosses Rs 100 crore

2002

  • State-of-the-art sterile facility, Plant II commissioned at Verna Goa

2003

  • UK-MHRA approval for the Solid Dosage facility at Plant I
  • Exports to regulated markets commence
  • First contract for Dossier Development with European company
  • Domestic Marketing makes a foray into the lifestyle segment

2004

  • First Contract for Development services with US Company
  • Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd
  • Four Patent applications filed
  • Company jumps five ranks in two years in the ORG-IMS Retail Audit

2005

  • First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa
  • Development Contracts for injectable products signed with a US Company
  • Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant
  • Shares of the Company listed on BSE and NSE

2006

  • US-FDA approval for Ophthalmic facility, Plant-II in GOA
  • Contract signed for supply of 18 generic products to German Market
  • 2 ANDAs filed with USFDA
  • Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh
  • New R&D Centre at Rabale, near Mumbai becomes functional
  • Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA
  • UK-MHRA approval for Creams & Ointments facility
  • Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing
  • Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards
  • Launch of Surge - a specialty marketing division

2007

  • ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I
  • Commencement of exports to the US markets
  • Launch of Warren-Excel and Spera - two specialty marketing divisions

2008

  • IDMA Quality Excellence Awards 2008 - The Sterile Facility at Goa Plant II received the Gold Award and the Solid Dosage Forms and Externals Facility at Goa Plant I received the Silver Award
  • TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams &Ointments Dosage forms at GOA Plant I
  • First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA
  • Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant
  • MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II

2009

  • UK-MHRA approval for the Solid Oral Dosage forms at Baddi Plant
  • Export sales exceeded Rs. 1 Billion in the FY 08-09
  • Successfully faced Slovenia audit for the Sterile Facility at Goa Plant II for the Injections Area

2010

  • Indoco Remedies teams up with ASPEN, South Africa by licensing out intellectual property (dossiers) for marketing its products in emerging markets covering 30 countries, including SA, Brazil, Mexico, Venezuela, Russia & Australia
  • Indoco Remedies licenses out technology to Watson Pharmaceuticals Inc. USA. Under the terms of profit sharing agreement, Indoco will develop, manufacture and supply a basket of sterile products to Watson for the US market

2011

  • Indoco received the Silver Quality Excellence Award for Sterile Manufacturing Facility in Goa and Solid Dosages Facility in Baddi (HimachalPradesh) at IDMA's Golden Jubilee celebrations

2012

  • Indoco announced the signing of an agreement with DSM, a € 9 billion Company, for commercial cooperation for Active Pharmaceutical Ingredients (APIs). Indoco and DSM have formed a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO
  • Innovation in Quality Award at CPhI Pharma Awards

2014

  • Inauguration of New GLP Analytical facility for Formulation
  • US-FDA approves Sterile (Plant II) and Solid Dosages (Plant III) facilities in Goa
  • IDMA Best Patent Award for Tazarotene & Adapalene

2015

  • Indoco wins IDMA Patent Appreciation Award for Betaxolol
  • Indoco acquires Piramal's Clinical Research division

2016

  • Indoco Honoured with the IDMA Best Patent Award for Three International Patents
  • Indoco achieves a milestone of Rs1000 crore
  • Indoco acquires Oral Solid Dosage manufacturing facility in Baddi from Micro Labs Ltd., Bangalore
  • Indoco's Allopurinol ANDA gets USFDA approval
  • Indoco climbs 187 ranks up - Fortune India
  • Indoco receives USFDA approval for solid dosages Plant I in Goa
  • Indoco honoured with the 'Best Patent Award' by PHARMEXCIL in the Bulk Drugs / API category

2017

  • Indoco receives the Express Pharma Export Excellence Award 2017
  • Indoco receives UKMHRA approval for solid dosages Plant I in Goa
  • Indoco receives the IDMA Best Patent Award for four API Process Patents
  • Indoco receives patent grant for Linezolid & Brinzolamide (FDFs) from United States Patent and Trademark Office (USPTO)

2018

  • Indoco commissions New API manufacturing facility at Patalganga
  • Indoco's Goa Plant II & III clears USFDA inspection
  • Indoco's API manufacturing facilities at Patalganga and Rabale successfully clear USFDA inspection
  • Indoco's API Patalganga site receives Renewed Accreditation Certificate from The Pharmaceuticals and Medical Devices Agency (PMDA), Japan
  • Indoco receives the IDMA Best Indian Patent Award for five API Process Patents
  • Indoco's Goa plant III receives EU GMP certification

2019

  • Indoco's Clinical Research Organisation receives zero 483s from USFDA
  • Indoco's stalwart brand CYCLOPAM crosses Rs 100 crore sales (as per IMS)
  • Indoco successfully completes UK-MHRA inspection at Goa Plant II
  • UK-MHRA reinstates full GMP status for Indoco's Goa Plant I
  • USFDA clears Indoco's Goa Plant II & III
  • Indoco gets European Patent Grant for unique process of Brinzolamide Eye Drops
  • Indoco wins the IDMA Formulations Patent Award 2017-18 for 2 International and 1 Indian patent
  • Indoco's new solid dosages facility at Baddi receives UK-MHRA approva
  • Indoco's Sterile Manufacturing Facility (Plant II) Clears USFDA Inspection

2020

  • Indoco receives USFDA approval for Apixaban Tablets 2.5 mg & 5 mg
  • Indoco awarded with the IDMA Formulations Best Patent Award 2018-19 for 2 formulation patents - Diclofenac & Quetiapine
  • Olopatadine ANDA filed from Indoco's Goa Plant II receives USFDA approval
  • AnaCipher Clinical Research receives BE study approval from WHO
  • First consignment of Glycopyrrolate Injection dispatched from Goa Plant II for launch in USA
  • Indoco receives USFDA approval for Succinylcholine Chloride Injection USP
  • Indoco receives USFDA approval for Olanzapine Tablets
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.